Gilead stops last PhIII of CD47 drug, citing FDA hold, higher risk of death in treatment arm

Gilead discontinued its remaining Phase III study of magrolimab, an anti-CD47 antibody that the company was testing for acute myeloid leukemia and its precursor disease, and it will not pursue future work on this therapy in blood cancers.

In an interim analysis, patients who received magrolimab had an increased risk of death compared to those who received standard care with AbbVie and Roche’s Venclexta and azacitidine. Gilead said Wednesday that the increased risk was “primarily driven by infections and respiratory failure.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Four years after shelter-in-place, covid-19 misinformation persists

From spring break parties to Mardi Gras, many people remember the last major “normal” thing they did before the novel coronavirus pandemic dawned, forcing governments

April 1, 2024

Double whammy: Stroke and neck artery tear increase heart attack risk in the first year

Heart attack risk almost doubles in the first year after a stroke or when combined with a tear in a neck artery wall, however, a

February 1, 2024

Review finds correlation between milk oligosaccharides and infant brain development

In a recent article published in Nutrients, researchers investigated the current evidence of the impact of milk oligosaccharides (MOS) on early life neurocognitive and brain development.

August 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.